by Portfolio Grader | September 4, 2013 11:00 am
This week, five Biotechnology stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) is making progress this week as its rating of C (“hold”) from last week increases to a B (“buy”) rating this week. ARIAD Pharmaceuticals is an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients. For more information, get Portfolio Grader’s complete analysis of ARIA stock.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) improves from a C to a B rating this week. Neurocrine Biosciences is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. For more information, get Portfolio Grader’s complete analysis of NBIX stock.
Array BioPharma (NASDAQ:ARRY) boosts its rating from a C to a B this week. Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. For more information, get Portfolio Grader’s complete analysis of ARRY stock.
This week, Celldex Therapeutics, Inc. (NASDAQ:CLDX) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). Celldex Therapeutics is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. The stock price has risen 6.7% over the past month, better than the 1.3% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of CLDX stock.
This week, Insmed Incorporated’s (NASDAQ:INSM) ratings are up from a C last week to a B. Insmed develops and commercializes drugs that treat metabolic diseases, endocrine disorders and oncology. Wall Street seems to agree with the upgrade and has propelled the stock up 28.8% over the past month. For more information, get Portfolio Grader’s complete analysis of INSM stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
Source URL: http://investorplace.com/2013/09/5-biotechnology-stocks-to-buy-now-aria-nbix-arry-18/
Short URL: http://investorplace.com/?p=396957
Copyright ©2013 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.